Subscribe To
KDNY / Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Content Topics
Chinook
Therapeutics
Present
Oppenheimer
33rd
Annual
Healthcare
Conference
Stock
KDNY
KDNY News
By GuruFocus
August 2, 2023
Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)
On August 1, 2023, Andrew King, the Chief Scientific Officer of Chinook Therapeutics Inc ( KDNY , Financial), sold 1,168 shares of the company. This m more_horizontal
By The Motley Fool
June 20, 2023
2 Surging Healthcare Stocks With More Fuel in the Tank
Shares of two biotech stocks are way up over the past month thanks to impressive clinical trial results for the drugs they're developing. Chinook Ther more_horizontal
By MarketBeat
June 13, 2023
Novartis Stock Screams Value After Chinook Therapeutics Buyout
That value proposition took a huge step forward on Monday when Novartis announced a $3.2 billion acquisition of Seattle-based biotechnology company Ch more_horizontal
By InvestorPlace
June 12, 2023
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
Chinook Therapeutics (NASDAQ: KDNY ) has been surging all day. Why? KDNY stock surged on news that multinational pharmaceutical giant Novartis (NYSE: more_horizontal
By GlobeNewsWire
June 12, 2023
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, developmen more_horizontal
By Market Watch
June 12, 2023
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, more_horizontal
By The Motley Fool
June 12, 2023
Why Shares of Chinook Therapeutics Skyrocketed On Monday
Novartis has agreed to buy out Chinook in a deal that could be worth $3.5 billion. Chinook is a clinical-stage biotech. more_horizontal
By Investopedia
June 12, 2023
Chinook Therapeutics Shares Soar on Novartis Purchase
Novartis agreed to buy Chinook Therapeutics for up to $3.5 billion. more_horizontal